ArticleJournal of thoracic disease2021

Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada.

Kirstin Perdrizet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.